Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction

医学 耐受性 射血分数 心力衰竭 临床终点 随机对照试验 利尿剂 利钠肽 内科学 心脏病学 不利影响 安慰剂 病理 替代医学
作者
Mihai Gheorghiade,Stephen J. Greene,Javed Butler,Gerasimos Filippatos,Carolyn S.P. Lam,Aldo P. Maggioni,Piotr Ponikowski,Sanjiv J. Shah,Scott D. Solomon,Elisabeth Kraigher‐Krainer,Eliana T. Samano,Katharina Müller,Lothar Roessig,Burkert Pieske
出处
期刊:JAMA [American Medical Association]
卷期号:314 (21): 2251-2251 被引量:325
标识
DOI:10.1001/jama.2015.15734
摘要

Worsening chronic heart failure (HF) is a major public health problem.To determine the optimal dose and tolerability of vericiguat, a soluble guanylate cyclase stimulator, in patients with worsening chronic HF and reduced left ventricular ejection fraction (LVEF).Dose-finding phase 2 study that randomized 456 patients across Europe, North America, and Asia between November 2013 and January 2015, with follow-up ending June 2015. Patients were clinically stable with LVEF less than 45% within 4 weeks of a worsening chronic HF event, defined as worsening signs and symptoms of congestion and elevated natriuretic peptide level requiring hospitalization or outpatient intravenous diuretic.Placebo (n = 92) or 1 of 4 daily target doses of oral vericiguat (1.25 mg [n = 91], 2.5 mg [n = 91], 5 mg [n = 91], 10 mg [n = 91]) for 12 weeks.The primary end point was change from baseline to week 12 in log-transformed level of N-terminal pro-B-type natriuretic peptide (NT-proBNP). The primary analysis specified pooled comparison of the 3 highest-dose vericiguat groups with placebo, and secondary analysis evaluated a dose-response relationship with vericiguat and the primary end point.Overall, 351 patients (77.0%) completed treatment with the study drug with valid 12-week NT-proBNP levels and no major protocol deviation and were eligible for primary end point evaluation. In primary analysis, change in log-transformed NT-proBNP levels from baseline to week 12 was not significantly different between the pooled vericiguat group (log-transformed: baseline, 7.969; 12 weeks, 7.567; difference, -0.402; geometric means: baseline, 2890 pg/mL; 12 weeks, 1932 pg/mL) and placebo (log-transformed: baseline, 8.283; 12 weeks, 8.002; difference, -0.280; geometric means: baseline, 3955 pg/mL; 12 weeks, 2988 pg/mL) (difference of means, -0.122; 90% CI, -0.32 to 0.07; ratio of geometric means, 0.885, 90% CI, 0.73-1.08; P = .15). The exploratory secondary analysis suggested a dose-response relationship whereby higher vericiguat doses were associated with greater reductions in NT-proBNP level (P < .02). Rates of any adverse event were 77.2% and 71.4% among the placebo and 10-mg vericiguat groups, respectively.Among patients with worsening chronic HF and reduced LVEF, compared with placebo, vericiguat did not have a statistically significant effect on change in NT-proBNP level at 12 weeks but was well-tolerated. Further clinical trials of vericiguat based on the dose-response relationship in this study are needed to determine the potential role of this drug for patients with worsening chronic HF.clinicaltrials.gov Identifier: NCT01951625.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
威武的沂完成签到,获得积分10
1秒前
3秒前
4秒前
6秒前
笨笨青筠完成签到 ,获得积分10
9秒前
mengmenglv完成签到 ,获得积分0
9秒前
Tonald Yang完成签到 ,获得积分20
12秒前
13秒前
落后的怀梦完成签到 ,获得积分10
14秒前
陈坤完成签到,获得积分10
16秒前
量子星尘发布了新的文献求助10
18秒前
斯文败类应助zgx采纳,获得10
19秒前
默默完成签到 ,获得积分10
19秒前
KY Mr.WANG完成签到,获得积分10
19秒前
33秒前
guoxingliu完成签到,获得积分10
37秒前
45秒前
阳佟水蓉完成签到,获得积分10
46秒前
gdgd完成签到,获得积分10
49秒前
量子星尘发布了新的文献求助10
51秒前
叮叮当当完成签到,获得积分10
53秒前
56秒前
56秒前
电致阿光完成签到,获得积分10
57秒前
ccc完成签到 ,获得积分10
59秒前
1分钟前
zgx发布了新的文献求助10
1分钟前
i2stay完成签到,获得积分10
1分钟前
馒头完成签到,获得积分10
1分钟前
MS903完成签到,获得积分10
1分钟前
CJW完成签到 ,获得积分10
1分钟前
韧迹完成签到 ,获得积分0
1分钟前
mmd完成签到 ,获得积分10
1分钟前
七一安完成签到 ,获得积分10
1分钟前
浪麻麻完成签到 ,获得积分10
1分钟前
包容的剑完成签到 ,获得积分10
1分钟前
等待的大炮完成签到,获得积分10
1分钟前
注水萝卜完成签到 ,获得积分10
1分钟前
Chem34完成签到,获得积分10
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022